It's facing an uphill slope | Just say "Yes" |
Finimize

Presented by TravelPerk

Hi John, here's what you need to know for November 26th in 3:10 minutes.

☕️ Finimized over a Vienna at the Gastromarket Balchug in Moscow, Russia (-4°C/25°F 🌧)

⏳ Keep it brief

  • The London transport regulator revoked Uber’s license – and investors sent its stock down 6%
  • Swiss pharmaceutical giant Novartis is buying US drugmaker The Medicines Company for $9.7 billion

London And Dusted

London And Dusted

What’s Going On Here?

London’s transport authority TfL halted Uber in its tracks on Monday by revoking its operating license – and the ride-hailing company’s investors slammed on the brakes, initially sending its shares down 6% (tweet this).

What Does This Mean?

Uber first hit London traffic in 2017, when TfL revoked its license. It’s since been granted two extensions, but TfL has now refused to renew that license again – alleging that the company uses unauthorized drivers at the expense of Londoners’ safety.

Uber’s shares initially dropped 6%, but investors relaxed a little once they’d read the small print: Uber’s still allowed to operate while it appeals TfL’s decision. Even so, there's continued uncertainty surrounding Uber’s access to its biggest European market – and whether that’ll encourage overseas regulators to start investigating the company too.

Why Should I Care?

For markets: Storm in a teacup?
This license issue is yet another problem for a company many Londoners are already avoiding in favor of France’s Kapten and Estonia’s Bolt. More competition means lower prices, and that might be problematic for Uber, which needs to prove it can make a profit. The car-sharing company’s also in the middle of a legal battle with the UK courts, which want Uber’s drivers to have the same benefits as full-time employees. With such a bumpy road ahead, it’s maybe no surprise that shareholders – including its founder – are jumping ship: Uber's stock has fallen 13% in the last month.

The bigger picture: Play by the rules.
Fellow “sharing economy” startup Airbnb is going through similar troubles. Governments in Paris, Barcelona, San Francisco, and New York City have all cracked down on the company, while the FBI is currently investigating its role in hosting scammers. And after a shooting at Halloween, Airbnb’s now announced a new verification scheme. It’s likely trying to get its house in order ahead of its planned initial public offering next year.

Why Uber’s stock moved instantly, then bounced back

Listen now

Why Uber’s stock moved instantly, then bounced back

13:15

Whatsapp

Got a question about this article? Ask us here

✈️ Travel management that saves you money

With our friends at TravelPerk, you’ll get access to in-depth data and actionable insights – helping you control your company’s travel spend and optimize your travel program in one place. With the world’s top-rated travel management software, you’ll make corporate travel easier for you and your company’s globetrotters. Request a demo

This sponsored section likes the way rain sounds on its window.
Want to advertise with us too? Get in touch

Pill-Poppins

Pill-Poppins

What’s Going On Here?

Swiss pharmaceutical giant Novartis announced it’s buying a promising US drugmaker: the $9.7 billion price tag might be a little hard to swallow, but a spoonful of sugar should help The Medicines Company go down.

What Does This Mean?

Novartis has made a string of acquisitions lately, and it’s likely decided to add The Medicines Company to that roster because of a particularly encouraging drug. The treatment looks set to help the millions at risk of cholesterol-related heart problems – making the drug a potential blockbuster if it’s approved. That might explain why The Medicines Company’s share price had tripled this year, even before the deal was announced…

Novartis’s purchase is its CEO’s latest attempt to transform the pharma company. Since he took the helm almost two years ago, he’s been aggressively getting rid of parts of the company not important to its core business, focusing instead on buying up the real money-spinners: cutting-edge cancer drugs and treatments for widespread diseases.

Why Should I Care?

The bigger picture: Drug deals.
Big pharma companies have recently tended to buy other companies’ drugs to keep their portfolios fully stocked, rather than develop their own. Novartis, for one, plans to spend up to 5% of its market value every year on takeovers. It may be more expensive to buy out an entire company than create a drug from scratch, sure. But it’s safer, too: a pharma company can acquire a proven treatment that’s already passed its initial trial stages.

Zooming out: Merger Monday.
Another takeover making the rounds on Monday was luxury conglomerate LVMH, which bought US jeweler Tiffany & Co in the biggest luxury goods deal ever. LVMH agreed to pay a sparkling $16 billion for the jeweler – $1 billion more than it’d previously offered. Tiffany's will hopefully enable it to better challenge Cartier-owner Richemont for dominance in the global jewelry business – one of the fastest-growing categories in the luxury goods sector.

Why Big Pharma wouldn't survive without little pharma

Listen now

Why Big Pharma wouldn't survive without little pharma

17:12

Whatsapp

Got a question about this article? Ask us here

💬 Quote of the day

“When life gets tangled, there is something so reassuring about climbing a mountain. The challenge is unambiguous.”

– Stacy Allison (the first American woman to summit Mount Everest)

Tweet this

TK-Banner

📚 What we're reading

  • The biggest podcasts of the last ten years (AV Club)
  • We’ve caught up with Futurama (New Scientist)
  • What goes into designing a baby (Cosmos)
Share Finimize. Become an Insider.

Share your unique link with friends, when they sign up you'll earn new rewards and upgrades. Track your progress here.

Copy and share your link:
https://finimize.com/invite?kid=12T6MV

We'd love to hear your thoughts. Give feedback

Image credits: Valentina Proskurina, V.Lawrence - Shutterstock, Dielmann - pixabay.com | Walt Disney, Traci J. Brooks Studios